<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387659</url>
  </required_header>
  <id_info>
    <org_study_id>10-244</org_study_id>
    <nct_id>NCT01387659</nct_id>
  </id_info>
  <brief_title>Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations</brief_title>
  <official_title>Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the tolerability of Myfortic®/Simulect® combination in&#xD;
      diabetic patients in a steroid free regimen. Due to the diverse ethnicity of our transplant&#xD;
      recipient population, the study will determine any different responses, including&#xD;
      autoimmunity, between Hispanic, and Caucasian, patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myfortic® is an enteric-coated formulation of the sodium salt derivative of mycophenolic acid&#xD;
      (MPA) that is administered to control kidney graft rejection. Myfortic® was developed to&#xD;
      improve MPA-related upper gastrointestinal (GI) side effects by delaying the release of MPA&#xD;
      until it reaches the large surface of the small bowel. Approximately half of all the kidney&#xD;
      transplant recipients in the United States have diabetes mellitus. A recent analysis of&#xD;
      approximately 30,000 kidney transplant recipients included in the U.S. Renal Data System&#xD;
      showed that 42% of patients had pre-transplant diabetes (1). Moreover, 15% to 20% of patients&#xD;
      develop diabetes after transplantation, a condition that is commonly known as post-diabetes&#xD;
      mellitus (1-3). It was previously shown that the rate and extent of MPA absorption is&#xD;
      minimally affected by diabetes (4). Limited data is available in the current literature on&#xD;
      Myfortic® and Simulect® based therapy in diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to slow enrollment&#xD;
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of Myfortic in combination with Simulect and Tacrolimus without steroids</measure>
    <time_frame>24 months</time_frame>
    <description>Assure that immunosuppression protects graft function by decreased incidence of rejection and side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI complications</measure>
    <time_frame>24 months</time_frame>
    <description>Gastric emptying test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function</measure>
    <time_frame>24 months</time_frame>
    <description>Renal function assessed by serum creatinine and calculating creatinine clearance.&#xD;
Pancreas function assessed by glucose control, exogenous insulin requirement, HgbA1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy proven rejection</measure>
    <time_frame>24 months</time_frame>
    <description>Renal graft core biopsy will be performed on all suspected rejection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Diabetes</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Transplant recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive identical drug treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastric emptying test</intervention_name>
    <description>Gastric emptying tests will be performed at baseline, 6 months and 12 months</description>
    <arm_group_label>Transplant recipients</arm_group_label>
    <other_name>Gastric motility</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (age 18 to 65 years of age), male or female Hispanic or Caucasian.&#xD;
&#xD;
          2. Primary kidney or kidney transplant patients (cadaveric, living related, or living&#xD;
             unrelated)&#xD;
&#xD;
          3. Written inform consent obtained. The patients are willing to participate in the study&#xD;
             at UTMB.&#xD;
&#xD;
          4. Female with negative pregnancy test.&#xD;
&#xD;
          5. PRA &lt; 20 %.&#xD;
&#xD;
          6. En-blocks and two kidneys (tx'd at the same time) will be allowed.&#xD;
&#xD;
          7. Cold Ischemia time ≤ 30 hrs&#xD;
&#xD;
          8. Hep C patients will be allowed to enroll in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multi-organ transplants&#xD;
&#xD;
          2. Transplant from non-heart beating donor (NHBD) or dual transplants&#xD;
&#xD;
          3. A-B-O incompatible or positive cross match&#xD;
&#xD;
          4. Conditions which significantly alter the absorption, distribution, and metabolism&#xD;
             (except for diarrhea) of medications.&#xD;
&#xD;
          5. Women of childbearing potential not using contraception method(s) as well as women who&#xD;
             are breastfeeding&#xD;
&#xD;
          6. Inability to tolerate oral medications&#xD;
&#xD;
          7. Inability to sign a written consent form or to cooperate with investigators&#xD;
&#xD;
          8. Use of an investigational medication in the past 30 days.&#xD;
&#xD;
          9. Patients with severe medical condition(s) that in the view of the investigator&#xD;
             prohibits participation in the study (specify as required)&#xD;
&#xD;
         10. HIV positive patients&#xD;
&#xD;
         11. History of psychosocial instability&#xD;
&#xD;
         12. Mental incompetence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Cicalese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myfortic</keyword>
  <keyword>Simulect</keyword>
  <keyword>Steroids</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Transplant</keyword>
  <keyword>Gastric emptying</keyword>
  <keyword>Gastric motility</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

